Business
Airbnb 2024 Summer Release
Airbnb co-founder and CEO Brian Chesky onstage this spring, introducing Icons, a new category of experiences hosted by big names in music, film, television, art, and sports. (Jesse Grant/Getty Images for Airbnb)
By The Book

People aren’t booking Airbnbs far in advance anymore. It's causing huge problems for the company.

A comedown on “revenge travel” after the pandemic, as well as consumers who feel like they’re on shaky ground, are likely contributing to hesitancy in booking early.

Rani Molla

People are still booking plenty of Airbnbs, they’re just waiting longer to do so than they had been in the halcyon travel days of people recovering from the early pandemic.

Airbnb beat revenue but missed earnings expectations in the second quarter, thanks mostly to an increase in income taxes. The stock was down 14% premarket following Tuesday’s earnings report after the bell.

What was probably most disturbing to investors, though, was Airbnb saying it was seeing shorter booking lead times globally and some signs of slowing demand from US guests.

But to be fair, those lead times look a lot more like what they used to, before fear over pandemic and subsequent “revenge travel” sent sent booking lead times way down, then way up.

On the earnings call, Airbnb CFO Ellie Mertz broke that down:

What you did see through the path of COVID was, initially, we saw a massive reduction in lead time, because people had no confidence in terms of their ability to book far out. That reversed in, say, the 2022 to 2023 time period, where people are so eager to travel that they were booking way in advance of their kind of normalized patterns to make sure that they had the trip on the book, they got the most attractive listing at the best price by booking early. And I think, fast forward to 2024, you're seeing up through Q2, a very much return to normal.

In other words, the second quarter of this year had similar booking lead times to the second quarter of 2019, pre-pandemic. More recently, though, particularly in July, she said, lead times have shrunk even more.

The hesitance is likely a result of the current shaky-feeling economic situation, as consumers ingest recent disappointing economic indicators like consumer spending and unemployment rates.

“From time to time, whether it be a new COVID variant, whether it be a macro headline, whether it be like last year, the outbreak of war in Israel, people from time to time have moments where they are not booking in the same timeframe that they did in prior periods and that's what we're tracking closely right now,” Mertz said.

To an extent, declines in lead times have been balanced out by “strong growth” in shorter lead booking times, for say the next weekend up to a few weeks from now.

“It's not that consumers are not necessarily going to book that trip for Thanksgiving or Christmas, it just appears that they have not booked it yet,” Mertz said.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26
2025 WWD Beauty CEO Summit - Day 2

CFO Mandy Fields sees e.l.f. Beauty in growth mode, as company beats on sales and earnings

The new owner of rhode beat estimates for its fiscal third quarter and boosted its guidance for the full year, even as headwinds in the UK and Germany continued.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.